Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970199 | 0.83 | PDE2A (0.52) | PDE2AKDM1AAKR1C3AKR1C2PTGS1 | |
| SCHEMBL17431626 | 0.73 | PDE2A (0.46) | PDE2AKDM1AAKR1C3AKR1C2PTGS1 | |
| SCHEMBL944794 | 0.71 | PDE2A (0.44) | PDE2AKDM1AAKR1C3AKR1C2PTGS1 | |
| SCHEMBL15146224 | 0.69 | ALDH1A1 (0.41) | PDE2AKDM1AAKR1C3AKR1C2PTGS1 | |
| SCHEMBL2220244 | 0.69 | CYP2A6 (0.46) | PDE2A | |
| SCHEMBL944658 | 0.69 | LMNA (0.50) | PDE2AKDM1AHAO1 | |
| SCHEMBL18656576 | 0.69 | PDE2A (0.42) | PDE2AKDM1AAKR1C3AKR1C2PTGS1 | |
| SCHEMBL2900759 | 0.69 | PDE2A (0.42) | PDE2AKDM1AAKR1C3AKR1C2PTGS1 | |
| SCHEMBL21585264 | 0.69 | PDE2A (0.48) | PDE2AKDM1AAKR1C3AKR1C2PTGS1 | |
| SCHEMBL240645 | 0.69 | MEN1 (0.50) | PDE2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023210378-A1 | COMPOUND, COMPOSITION, SURFACE TREATMENT AGENT, ARTICLE MANUFACTURING METHOD, AND ARTICLE | ＡＧＣ株式会社 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023204021-A1 | COMPOUND, COMPOSITION, SURFACE TREATMENT AGENT, METHOD FOR MANUFACTURING ARTICLE, AND ARTICLE | ＡＧＣ株式会社 | 2023-10-26 | — | — | WO | disclosed |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9663496-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2016-08-11 | — | — | US | disclosed |
| US-9266856-B2 | AMPK—activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150087673-A1 | METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8987303-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8980921-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140315884-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8809370-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8791136-B2 | Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130267701-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2013-10-10 | — | — | US | disclosed |
| US-20130267702-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2013-10-10 | — | — | US | disclosed |
| US-20130203987-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087673-A1 | METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS | PRKAG3, PRKAG1, PRKAG2 | PDE2A 714/4885KDM1A 2564/4885AKR1C3 497/4885 |
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PDE2A 1089/4885KDM1A 1452/4885AKR1C3 446/4885 |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | AK2, PC, PRKAG2 | PDE2A 1059/4885KDM1A 1511/4885AKR1C3 638/4885 |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PDE2A 1089/4885KDM1A 1452/4885AKR1C3 446/4885 |
| US-20140315884-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PDE2A 1089/4885KDM1A 1452/4885AKR1C3 446/4885 |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | PDE2A 1089/4885KDM1A 1452/4885AKR1C3 446/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | PDE2A 1089/4885KDM1A 1452/4885AKR1C3 446/4885 |
| US-20130203987-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PDE2A 1089/4885KDM1A 1452/4885AKR1C3 446/4885 |
| US-20130267702-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PDE2A 1089/4885KDM1A 1452/4885AKR1C3 446/4885 |
| US-20130267701-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PDE2A 1089/4885KDM1A 1452/4885AKR1C3 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.